Illumina is leveraging our leadership in next-generation sequencing to deliver in vitro diagnostic (IVD) solutions to improve the management of cancer patients in the clinic. We are partnering with leading biotechnology companies to develop companion diagnostics for best-in-class therapeutics.
Distributable diagnostic solutions, such as companion diagnostics (CDx) versions of TruSight Tumor 170 and TruSight Oncology 500, will enable labs to perform precision medicine testing in-house.
Illumina and Loxo Oncology Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion DiagnosticsView Press Release
Illumina and Bristol-Myers Squibb Collaborate to Develop and Commercialize Companion Diagnostics for Oncology ImmunotherapiesView Press Release
TruSight Tumor 170 is a DNA- and RNA-based solution to provide comprehensive variant analysis for solid tumors. With the launch of this product, Illumina has developed the underlying chemistry and workflow to enable a modular and scalable approach to future IVD development in tissue and blood.
This platform, called TruSight Oncology, provides the building blocks for future products in our pipeline. This chemistry platform can be extended to whole-exome and whole-genome sequencing, as well as sequencing RNA transcripts for truly comprehensive profiling of cancers.
We believe that TruSight Oncology will be highly impactful, especially in enabling the development of immunotherapy and circulating tumor DNA (ctDNA) monitoring applications.